share_log

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 3.8% Higher

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 3.8% Higher

Armata Pharmicals(纽约证券交易所美国证券交易所代码:ARMP)交易价格上涨3.8%
Defense World ·  2023/04/20 14:05

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Rating)'s share price traded up 3.8% during mid-day trading on Wednesday . The stock traded as high as $1.64 and last traded at $1.62. 801 shares were traded during mid-day trading, a decline of 95% from the average session volume of 16,446 shares. The stock had previously closed at $1.56.

Armata Pharmicals, Inc.(纽约证券交易所美国证券交易所代码:ARMP — 获取评级)的股价在周三午盘交易中上涨了3.8%。该股交易价格高达1.64美元,最后一次交易价格为1.62美元。午盘交易中交易了801股,较平均交易量16,446股下降了95%。该股此前收于1.56美元。

Analysts Set New Price Targets

分析师设定了新的价格目标

Separately, HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a research report on Friday, March 17th.

另外,HC Wainwright在3月17日星期五的一份研究报告中重新发布了 “买入” 评级,并对Armata Pharmicals的股票发布了7.00美元的目标价格。

Get
获取
Armata Pharmaceuticals
阿玛塔制药
alerts:
警报:

Armata Pharmaceuticals Stock Up 3.8 %

Armata Pharmicals股票上涨3.8%

The company has a market cap of $58.53 million, a PE ratio of -1.49 and a beta of 1.18.

该公司的市值为5853万美元,市盈率为-1.49,beta值为1.18。

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Rating) last announced its earnings results on Thursday, March 16th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.34 million. Armata Pharmaceuticals had a negative return on equity of 75.16% and a negative net margin of 670.26%. On average, equities analysts anticipate that Armata Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

Armata Pharmicals(NYSEAMERICAN: ARMP — 获取评级)最后一次公布财报是在3月16日星期四。该公司公布了本季度每股收益(0.29美元),比分析师普遍预期的(0.25美元)低了(0.04美元)。该公司在本季度的收入为105万美元,而市场普遍预期为134万美元。Armata Pharmicals的负股本回报率为75.16%,净利润率为负670.26%。股票分析师平均预计,Armata Pharmicals, Inc.将在本财年公布每股收益-1.31美元。

Institutional Trading of Armata Pharmaceuticals

阿玛塔制药的机构交易

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Armata Pharmaceuticals by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 273,150 shares of the company's stock worth $1,335,000 after acquiring an additional 10,400 shares in the last quarter. Northern Trust Corp purchased a new position in Armata Pharmaceuticals during the first quarter worth approximately $95,000. Renaissance Technologies LLC increased its position in shares of Armata Pharmaceuticals by 5.6% in the fourth quarter. Renaissance Technologies LLC now owns 73,696 shares of the company's stock worth $91,000 after acquiring an additional 3,900 shares in the last quarter. HRT Financial LP acquired a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth $52,000. Finally, Jane Street Group LLC acquired a new stake in Armata Pharmaceuticals during the 4th quarter valued at $25,000. Institutional investors and hedge funds own 3.76% of the company's stock.

一些对冲基金最近买入和卖出了该公司的股票。Vanguard Group Inc. 在第一季度将其在Armata Pharmicals的股份提高了4.0%。Vanguard Group Inc. 在上个季度又收购了10,400股股票后,现在拥有该公司273,150股股票,价值13.5万美元。北方信托公司在第一季度收购了Armata Pharmicals的新职位,价值约9.5万美元。Renaissance Technologies LLC在第四季度将其在Armata Pharmicals的股票头寸增加了5.Renaissance Technologies LLC在上个季度又收购了3,900股股票后,现在拥有该公司73,696股股票,价值91,000美元。HRT Financial LP在第四季度收购了价值52,000美元的Armata Pharmicals股票的新股份。最后,Jane Street Group LLC在第四季度收购了Armata Pharmicals的新股份,价值25,000美元。机构投资者和对冲基金拥有该公司3.76%的股票。

Armata Pharmaceuticals Company Profile

阿玛塔制药公司简介

(Get Rating)

(获取评级)

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

Armata Pharmicals, Inc是一家临床阶段的生物技术公司,专注于开发用于治疗耐药细菌感染的噬菌体疗法。该公司成立于2019年5月9日,总部位于加利福尼亚州洛杉矶。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Armata Pharmaceuticals (ARMP)
  • ASML Reports Massive Growth, Management Points To Sluggish 2023
  • Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
  • Mullen Automotive: Is The Bloom Off The Rose?
  • Diversified Abbott Laboratories Could Reverse And Move Higher
  • Okta Reversal In Progress While Catalysts Approach
  • 免费获取 StockNews.com 关于 Armata Pharmicals(ARMP)的研究报告的副本
  • ASML报告了大规模增长,管理层指出2023年表现疲软
  • 分析师 Boost 会让洛克希德·马丁公司的股价上涨、上涨和下跌吗?
  • Mullen Automotive:是玫瑰花的吗?
  • 多元化的雅培实验室可能会逆转并走高
  • 催化剂接近时Okta的逆转正在进行中

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收《阿玛塔制药日报》的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Armata Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发